4-羟基-6-甲基喹唑啉 | 19181-53-4

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 4-羟基-6-甲基喹唑啉
• 中文别名: 6-甲基-4-喹唑酮；4-甲基-6-喹唑酮；6-甲基-4-喹唑啉酮
• 英文名称: 6-methyl-3H-quinazolin-4-one
• 英文别名: 6-methylquinazolin-4(3H)-one；6-Methylquinazolin-4-one；6-methyl-4-hydroxyquinazoline；3,4-dihydro-4-oxo-6-methylquinazoline；6-Methylquinazolin-4-ol
• CAS: 19181-53-4
• 化学式: C₉H₈N₂O
• mdl: MFCD00174855
• 分子量: 160.175
• InChiKey: JUCDXPIFJIVICL-UHFFFAOYSA-N

物化性质

• 熔点：
  238-240
• 沸点：
  334.6±35.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Hydroxy-6-methylquinazoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Hydroxy-6-methylquinazoline
CAS number: 19181-53-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8N2O
Molecular weight: 160.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羟基-6-甲基喹唑啉 在 六氯环三磷腈 、 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  An efficient HCCP-mediated direct amination of quinazolin-4(3H)-ones

  摘要：

  An efficient direct amination of quinazolin-4(3H)-ones has been developed. Treatment of quinazolin-4(3H)-ones with HCCP, DIPEA, and N-contained nucleophiles in acetonitrile could be able to form the corresponding 4-aminoquinazoline derivatives. Under the optimal reaction conditions, the amination products were achieved in good yields. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.12.067
• 作为产物：
  描述：

  间甲基苯腈 在 盐酸 、 tin 作用下， 生成 4-羟基-6-甲基喹唑啉
  参考文献：
  名称：

  Findeklee, Chemische Berichte, 1905, vol. 38, p. 3555

  摘要：

  DOI：
• 作为试剂：
  描述：

  三乙胺 、 2-溴-4'-氟苯乙酮 在 4-羟基-6-甲基喹唑啉 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Kalinowska-Torz; Skwarski; Sobiak, Polish Journal of Chemistry, 1997, vol. 71, # 1, p. 57 - 62

  摘要：

  DOI：

文献信息

• Alkynyl and azido-substituted 4-anilinoquinazolines
  申请人：Pfizer Inc.

  公开号：US05747498A1

  公开（公告）日：1998-05-05

  The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.

  该发明涉及公式##STR1##的化合物及其药用盐，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、n和m如本文所定义。公式I的化合物在治疗高增殖性疾病，如癌症方面是有用的。该发明还涉及制备公式I化合物的方法以及在治疗高增殖性疾病中使用这些化合物的方法。
• Synthesis and antiviral bioactivity of novel (1E, 4E)-1-aryl-5-(2-(quinazolin-4-yloxy)phenyl)-1,4-pentadien-3-one derivatives
  作者：Hui Luo、Jiaju Liu、Linhong Jin、Deyu Hu、Zhen Chen、Song Yang、Jian Wu、Baoan Song

  DOI：10.1016/j.ejmech.2013.02.035

  日期：2013.5

  A series of novel (1E, 4E)-1-aryl-5-[2-(quinazolin-4-yloxy)phenyl]-1,4-pentadien-3-one derivatives were designed and synthesized by reacting substituent aldehyde with intermediates 4a–f. Antiviral bioassays indicated that most of the compounds exhibited promising ex vivo antiviral bioactivities against tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV) at 500 μg/mL. The relationship between

  通过取代醛与苯甲醛的反应合成了一系列新颖的（1 E，4 E）-1-芳基-5- [2-（喹唑啉-4-基氧基）苯基] -1,4-戊二烯-3-酮衍生物。中间体4a – f。抗病毒生物测定表明，大多数化合物在500μg/ mL的浓度下对烟草花叶病毒（TMV）和黄瓜花叶病毒（CMV）表现出有希望的离体抗病毒生物活性。还讨论了结构与抗病毒活性之间的关系。化合物5a，6e和6g在离体TMV上可具有大约50％的明显保护性生物活性（EC 50）分别为257.7、320.7和243.3μg/ mL。该研究首次证明（1 E，4 E）-1-芳基-5-（2-（喹唑啉-4-基氧基）苯基）-1,4-戊二烯-3-酮可用于开发潜力植物用杀病毒剂。
• Raf inhibitor compounds and methods of use thereof
  申请人：Miknis Greg

  公开号：US20070049603A1

  公开（公告）日：2007-03-01

  Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对抑制Raf激酶和治疗由此介导的疾病有用。公开了使用公式I的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV)<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS PAR PIPÉRIDIN, AYANT UNE ACTIVITÉ INHIBITRICE SUR LA RÉPLICATION DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV)
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：WO2016091774A1

  公开（公告）日：2016-06-16

  The invention concerns novel substituted bicyclic pyrazolo pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.

  这项发明涉及具有抗病毒活性的新型取代的双环吡唑嘧啶化合物，特别是对呼吸道合胞病毒（RSV）复制具有抑制活性的化合物。该发明还涉及制备这种新型化合物，包含这些化合物的组合物，以及用于治疗呼吸道合胞病毒感染的化合物。
• Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10702521B2

  公开（公告）日：2020-07-07

  The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

  本发明涉及治疗淋病双球菌感染的方法，包括向需要的受试者施用新型1,2-二氢-2a,5,8a-三氮杂蒽-3,8-二酮化合物：或其药学上可接受的盐和/或相应的药物组合物。